Historian -- an unsuccessful novelist." - H.L. Mencken
Today, we take a deeper look at a small biotech concern that has been very volatile in its history as a public company. However, it has potential catalysts on the horizon and has picked up some insider buying of late as well. A full investment analysis follows in the paragraphs below.
Company Overview:
Akebia Therapeutics, Inc. (AKBA) is a Cambridge, Massachusetts-based biopharmaceutical concern focused on the development of therapies for kidney diseases. The company has one commercial product marketed for two indications and one